文献速递胸部肿瘤

Ganetespib联合多西他赛对比多西他赛二线治疗晚期肺腺癌的随机III期研究(GALAXY-2)

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
PubMed 文献 · J Clin Oncol · 2019-12-12

GALAXY-2是一项国际III期随机试验,纳入677例晚期肺腺癌患者,比较Ganetespib联合多西他赛与多西他赛单药的二线疗效。

要点

  • Ganetespib联合多西他赛未改善晚期肺腺癌二线患者的总生存。
  • 联合组3/4级中性粒细胞减少发生率为30.9%,高于单药组的25%。

核心结论

  • 在晚期肺腺癌的二线治疗中,Ganetespib联合多西他赛相比多西他赛单药未能改善总生存。

研究设计与样本

  • 国际多中心随机III期试验,纳入677例IIIB或IV期肺腺癌患者,按1:1随机分配至Ganetespib联合多西他赛组(335例)或多西他赛单药组(337例)。

主要发现

  • 在LDH升高或EGFR/ALK野生型亚组中,联合治疗也未改善任何次要终点。
  • 两组最常见的3/4级不良事件均为中性粒细胞减少,联合组发生率为30.9%,单药组为25%。

临床怎么用

  • 不推荐在晚期肺腺癌二线治疗中将Ganetespib与多西他赛联合使用。

局限性

  • 试验因无效性分析提前终止,可能影响部分次要终点的统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ganetespib, a highly potent heat shock protein 90 inhibitor, blocks multiple oncogenic pathways, resulting in antitumor activity. We evaluated the combination of ganetespib and docetaxel for second-line therapy of patients with advanced adenocarcinoma of the lung. PATIENTS AND METHODS: In this international phase III trial, patients with stage IIIB or IV adenocarcinoma diagnosed > 6 months before study entry and 1 prior systemic therapy were randomly assigned (1:1) to ganetespib 150 mg/m2 on days 1 and 15 with docetaxel 75 mg/m2 on day 1 of a 21-day cycle or to docetaxel alone. The primary end point was overall survival (OS). RESULTS: Of 677 enrolled patients, 335 were randomly assigned to ganetespib and docetaxel and 337 were assigned to docetaxel. The trial was stopped early as a result of futility at a planned interim analysis. The median OS time was 10.9 months (95% CI, 9.0 to 12.3 months) in the ganetespib and docetaxel arm compared with 10.5 months (95% CI, 8.6 to 12.2 months) in docetaxel arm (hazard ratio [HR], 1.11; 95% CI, 0.899 to 1.372; P = .329). Median progression-free survival was 4.2 months in the ganetespib and docetaxel arm and 4.3 months in the docetaxel arm (HR, 1.16; 95% CI, 0.96 to 1.403; P = .119). The addition of ganetespib did not improve outcomes compared with docetaxel alone for any secondary end point, including survival in the elevated lactate dehydrogenase or EGFR and ALK wild-type populations. The most common grade 3 or 4 adverse event in both arms was neutropenia (30.9% with ganetespib and docetaxel v 25% with docetaxel). CONCLUSION: The addition of ganetespib to docetaxel did not result in improved survival for salvage therapy of patients with advanced-stage lung adenocarcinoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pillai RN, Fennell DA, Kovcin V, et al. Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). J Clin Oncol. 2019. PMID: 31829907. doi:10.1200/JCO.19.00816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。